HDAC Inhibitors via Hydroxamic Acid Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds for inhibiting histone deacetylase activity, while effective in treating cancer and other diseases, lack improved potency and bioavailability, necessitating the development of new inhibitors with enhanced properties.
Innovation Solution
Development of a novel class of compounds represented by specific chemical formulas that inhibit histone deacetylase, inducing terminal differentiation and apoptosis of neoplastic cells, and are suitable for treating various diseases, including cancer, autoimmune, and neurodegenerative disorders, with pharmaceutical compositions and safe dosing regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxamic acid derivatives are used to inhibit histone deacetylase, then biological activity as antitumor agents is achieved, but potency and bioavailability are insufficient
Solution Approach 1:
The patent modifies the hydroxamic acid derivative structure by changing chemical parameters - specifically replacing the hydroxamic acid moiety with alternative functional groups (amides, carbamates, ureas) and adjusting molecular weight, lipophilicity, and hydrogen bonding capacity to improve potency and bioavailability while maintaining HDAC inhibitory activity
Solution Approach 2:
The invention creates composite molecular structures combining HDAC inhibitor cores with various pharmacophoric groups and linkers, forming hybrid molecules that integrate multiple functional properties - antitumor activity, improved bioavailability, and enhanced potency - into a single compound
2Reliability
If new HDAC inhibitors with improved potency are developed, then therapeutic effectiveness is enhanced, but structural complexity increases
Solution Approach 1:
The patent divides the HDAC inhibitor molecule into distinct functional segments - a core inhibitor moiety, linker regions, and terminal pharmacophoric groups - allowing systematic optimization of each segment's contribution to potency while managing overall molecular complexity through modular design
Solution Approach 2:
The invention applies local quality by introducing specific functional groups at particular positions on the molecular scaffold to enhance binding affinity and selectivity for HDAC enzymes, rather than uniformly increasing complexity throughout the entire molecule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compounds effectively inhibit histone deacetylase, selectively inducing terminal differentiation and apoptosis of neoplastic cells, offering improved therapeutic options for cancer and other diseases with enhanced potency and bioavailability.
Implementation Method 1
These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells
Implementation Method 2
histone acetylation and deacetylation are mechanisms by which transcriptional regulation in a cell is achieved
Implementation Method 3
These effects are thought to occur through changes in the structure of chromatin by altering the affinity of histone proteins for coiled DNA in the nucleosome
Data Source
AI summary
The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.